AvalehtMOR • ETR
add
MorphoSys AG
Viimane sulgemishind
67,65 €
Tänane vahemik
67,65 € - 68,00 €
Aasta vahemik
14,52 € - 69,75 €
Turuväärtus
2,55 mld EUR
Keskmine maht
66,52 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
ETR
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (EUR) | märts 2024info | Y/Y muutus |
|---|---|---|
Käive | 27,54 mln | 13,11% |
Põhitegevusega seonduv kulu | 289,14 mln | 264,02% |
Puhastulu | −314,96 mln | −608,87% |
Puhaskasumimarginaal | −1,14 tuh | −526,67% |
Puhaskasum aktsia kohta | −8,27 | −529,19% |
EBITDA | −263,38 mln | −388,32% |
Tõhus maksumäär | 0,51% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (EUR) | märts 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 630,77 mln | −20,30% |
Kogu vara | 1,83 mld | −17,85% |
Kõik kohustused | 2,09 mld | −1,84% |
Kogu omakapital | −261,67 mln | — |
Emiteeritud aktsiate arv | 37,62 mln | — |
Hinna ja väärtuse suhe P/B | −9,72 | — |
Varade tasuvus | −34,27% | — |
Kapitali tasuvus | −41,11% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (EUR) | märts 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −314,96 mln | −608,87% |
Põhitegevuse rahakäive | −71,53 mln | 14,27% |
Investeeringute raha | 28,62 mln | 187,62% |
Finantseerimise raha | −950,28 tuh | 97,86% |
Raha ja raha ekvivalentide muutus | −27,24 mln | 75,37% |
Tasuta rahavoog | 246,91 mln | 1 523,66% |
Teave
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.
MorphoSys AG is listed on the Frankfurt Stock Exchange and on the US Nasdaq stock exchange. Novartis agreed to acquire the company in February 2024. Wikipedia
Tegevjuht
Asutatud
1992
Peakontor
Veebisait
Töötajate arv
464
